

## 6-Amino-5-Bromouracil Delay the Onset of Toxicity of *Cerastes cerastes* Venom in Albino Mice

Halima A Gbaj<sup>1</sup>, Inass A Sadawe<sup>1</sup>, Nisreen H Meiqal<sup>1</sup>, Salah M Bensaber<sup>1</sup>, Abdulathim AA Alshoushan<sup>2</sup>,  
Massaud Salem Maamar<sup>3</sup>, Anton Hermann<sup>4</sup> and Abdul M Gbaj<sup>1\*</sup>

<sup>1</sup>Department of Medicinal Chemistry, Faculty of Pharmacy, University of Tripoli, Libya

<sup>2</sup>Food and Drug Control Centre (LFDA), Tripoli, Libya

<sup>3</sup>Zoology Department, Faculty of Science, Tripoli University, Libya

<sup>4</sup>Department of Biosciences, University of Salzburg, Salzburg, Austria.

Received September 02, 2019; Accepted September 19, 2019; Published February 26, 2020

### ABSTRACT

Snake bite is a severe medical emergency in North Africa region and other parts of the world. When venom injected into the victim after the bite causes grave debilitating and life-threatening effects eventually resulting in mortality and morbidity. Snake venom phospholipases A<sub>2</sub> (PLA<sub>2</sub>) have local and systemic actions that induce pathophysiological effects in the victim. 6-Amino-5-bromo-1H-pyrimidine-2,4-dione (6-amino-5-bromouracil) is a derivative of uracil and has an inhibitory effect on many enzymes. Molecular docking and fluorescence studies were performed in order to determine the potential modes of action of 6-amino-5-bromouracil with phospholipases A<sub>2</sub>. 6-Amino-5-bromouracil showed hydrogen bonds with an active site of enzyme and changes in the fluorescent spectrum of PLA<sub>2</sub>. The achieved results revealed that 6-amino-5-bromouracil treated animals have shown to increase the mean survival time and the protection fold, but could not protect mice from death when used alone. The use of 6-amino-5-bromouracil could lead to prevent the snake venom toxicity and further chemical synthesis analogues and *in vivo* studies would be necessary to substantiate the obtained results.

**Keywords:** Snake bite, *Cerastes cerastes*, 6-amino-5-bromouracil, Fluorescence, Phospholipase A<sub>2</sub>, Molecular docking

**Abbreviations:** PLA<sub>2</sub>: Phospholipases A<sub>2</sub>; 6A5B: 6-Amino-5-Bromouracil

### INTRODUCTION

Snakebite is a foremost public health problem in numerous African countries including Libya, Algeria Egypt and Tunisia [1,2]. It is a meticulous confront, even though, in some parts of Africa, which is home for more than 400 snake species, of which about 30 venomous species, belonging to four snake families namely: Colubridae, Viperidae, Elapidae, Atractaspididae and they are appeared to cause human deaths, as reported by the World Health Organization [2]. *Cerastes cerastes* is one of the snakes commonly threatening human life in Libya. The *Cerastes cerastes* venom is containing numerous enzymes that have proteolytic activity and leads to multiple kinds of intoxications [3]. The lethal cause of snake venom mainly results from its active components mainly PLA<sub>2</sub>. *Cerastes cerastes* snake venoms cause proteolysis, shock, blood clotting, release of bioactive substances such as bradykinin and histamine, necrosis, hemorrhage and numerous other effects [4-6]. Necrosis might result from a direct action of

myotoxins or myotoxic PLA<sub>2</sub>s on plasma membranes of muscle cell or indirectly, as a consequence of blood vessel degeneration and ischemia caused by hemorrhaging. PLA<sub>2</sub>s interact with membrane phospholipid components which lead to promote release of intracellular creatine kinase, which might be used as a biomarker for myotoxic activity assessment [7,8]. The snake venom physiopathological processes encouraged researchers to obtain natural or chemically synthesised inhibitors.

**Corresponding author:** Abdul M Gbaj, Associate Professor of Genetics and Biochemistry, Department of Medicinal Chemistry, Faculty of Pharmacy, University of Tripoli, Libya, E-mail: [abdulgbaj4@hotmail.com](mailto:abdulgbaj4@hotmail.com)

**Citation:** Gbaj HA, Sadawe IA, Meiqal NH, Bensaber SM, Alshoushan AAA, et al. (2020) 6-Amino-5-Bromouracil Delay the Onset of Toxicity of *Cerastes cerastes* Venom in Albino Mice. J Vet Marine Sci, 2(1): 38-45.

**Copyright:** ©2020 Gbaj HA, Sadawe IA, Meiqal NH, Bensaber SM, Alshoushan AAA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Some PLA<sub>2</sub> inhibitors may be found in different organisms. Manoalide (A) is a non-steroidal sesquiterpenoid from the marine sponge *Luffariella variabilis*, while manoalide (B) was synthetically synthesized based on its natural analogue. These terpenoids compounds have irreversible inhibitory effects on numerous PLA<sub>2</sub>s obtained from snakes [9,10]. The phospholipase A<sub>2</sub> (PLA<sub>2</sub>) activity can be inhibited by some inhibitors as reported in the literature who have found that a chemical compound called varespladib and its orally bioavailable prodrug, methyl-varespladib had an inhibitory effect on PLA<sub>2</sub> (sPLA<sub>2</sub>) at nanomolar and picomolar concentrations against 28 medically vital snake venoms from six continents [11]. The aim of the paper was to study the inhibitory effect of 6-amino-5-bromouracil on phospholipase A<sub>2</sub> enzyme to treat snake envenomation using molecular docking and fluorescence studies.

## MATERIALS AND METHOD

### Preparation of aqueous 6-amino-5-bromouracil solution

A weight of 19 mg from 6-amino-5-bromouracil (Matrix Scientific, Columbia, and Catalog Number 078889) was dissolved in 100 µl DMSO and the solution was completed to 5 ml with 0.9% sodium chloride to give a final stock solution of 18.5 mM and stored at -20°C until use.

### Venoms

Snake (*Cerastes cerastes*,) venom was extracted by manual stimulation and were obtained in liquid forms, from the Department of Zoology, Faculty of Science, University of Tripoli (Libya) and stored at -20°C until use. An aliquot of 7.5 µl venom from the venoms was added to 800 µl of normal saline. A dose of 100 µl (100 ng) was intraperitoneally injected in 18 ± 2 g male Swiss Albino mice.

### Molecular docking

The starting geometry of the 6-amino-5-bromouracil was constructed using chem3D Ultra (version 8.0, Cambridge soft Com., USA). The optimized geometry of 6-amino-5-bromouracil with the lowest energy was used for molecular docking. Crystal structures of the crystal structure of cobra-venom phospholipase A<sub>2</sub> in a complex with a transition-state analogue (IPOB) was downloaded from the Protein Data Bank <https://www.rcsb.org/structure/IPOB>. Molecular dockings of 6-amino-5-bromouracil with IPOB was accomplished by Auto Dock 4.2 software from the Scripps Research Institute (TSRI) (<http://autodock.scripps.edu/>). Firstly, polar hydrogen atoms were added into protein molecules. Then, partial atomic charges of the phospholipase enzymes and 6-amino-5-bromouracil molecules were calculated using Kollman methods [12]. In the process of molecular docking, the grid maps of dimensions (62 Å × 62 Å × 62 Å) with a grid-point spacing of 0.376 Å and the grid boxes are centered. The number of genetic algorithm runs and the number of evaluations were set to 100. All other parameters were default settings. Cluster analysis was

performed on the results of docking by using a root mean square (RMS) tolerance of 2.0 Å, which was dependent on the binding free energy. Lastly, the dominating configuration of the binding complex of 6-amino-5-bromouracil and phospholipase A<sub>2</sub> enzyme fragments with minimum energy of binding were determined which relied strongly on the information of 3D structures of the phospholipase A<sub>2</sub> binding site and ultimately generated a series of phospholipase binding complex.

### Absorbance spectra

Absorbance spectra were measured on a Jenway UV-visible spectrophotometer, model 6505 (London, UK) using quartz cells of 1.00 cm path length. The UV-Vis absorbance spectra were recorded in the 200-500 nm range and spectral bandwidth of 3.0 nm. For the final spectrum of each solution analyzed baseline subtraction of the buffer solution was performed. The protein content of venoms samples was determined by the spectrophotometric method as described [13]. Bovine serum albumin (BSA, Sigma) was used for standard assays.

### Fluorescence spectra

Fluorescence emission and excitation spectra were measured using Jasco FP-6200 spectrofluorometer (Tokyo, Japan) using fluorescence 4-sided quartz cuvettes of 1.00 cm path length. The automatic shutter-on function was used to minimize photo bleaching of the sample. The selected wavelength chosen provided aggregate excitation of tryptophan and tyrosine residues. The emission spectrum was corrected for background fluorescence of the buffer. The changes of fluorescence emission intensity and fluorescence shifts were monitored in which the formation of the system was formed by sequential addition of aliquots of Tris buffer, *Cerastes cerastes* venom and finally 6-amino-5-bromouracil.

### Experimental animals

Swiss Albino male mice (18 ± 2 g) were used for the experiments. In order to reduce the contact caused by environmental alterations and handling during behavioral studies, mice were acclimatized to the Laboratory Animal Holding Center and laboratory surroundings for three days and at least 1 h before the experiments, respectively. Mice were kept under standard conditions with food (low protein diet) and water available *ad libitum*. The animals were housed six per cage in a light-controlled room (12 h light/dark cycle, light on 07:00 h) at 27°C and 65% relative humidity. All experiments were carried out between 11:30 and 14:00 h. Each test group consisted of at least six mice and each mouse was used only once. All animal experiments were conducted according to guidelines set by Institutional Animal Ethics Committee of University of Tripoli. Five groups of mice were used in this study. The first group of six mice received only 100 µl (100 ng of total protein) of the *Cerastes cerastes* venom (LD99 5 µg/kg). Groups 2-4 of six mice each (serving as treatment groups) were given an

equivalent amount of the *Cerastes cerastes* venom with 100  $\mu$ l, 200  $\mu$ l and 300  $\mu$ l of 6-amino-5-bromouracil (stock 18.5 mM) solution, respectively. Group 5 of six mice received 100  $\mu$ l of the *Cerastes cerastes* venom and ASV. The number of mortality was recorded within 24 h.

#### Calculation of LD99 of *Cerastes cerastes* venom

The median lethal dose (LD99) of *Cerastes cerastes* venom was determined according to the previously developed method [14,15]. A range of doses of venom in 800  $\mu$ l of physiological saline was injected intraperitoneally using groups of six mice for each venom dose. The LD99 was calculated with the confidence limit at 99% probability by the analysis of mortality occurring within 24 h of venom injection. The anti-lethal potentials of 6-amino-5-bromouracil (stock 18.5 mM) solution were determined against LD99 of *Cerastes cerastes* venom.

#### STATISTICAL ANALYSIS


The difference among various treated groups and control group were analysed using one-way-ANOVA followed using unpaired Student's t test. The results were expressed as the mean  $\pm$  SEM of the number of experiments done, with  $P < 0.05$  indicating significant difference between groups.

#### RESULTS AND DISCUSSION

##### Molecular docking analysis

**Table 1** shows the binding energies of 6-amino-5-bromouracil, Gel and cobra-venom phospholipase A<sub>2</sub> (IPOB) obtained by the molecular docking strategy. In this study, molecular dockings of the 6-amino-5-bromouracil and Gel with cobra-venom phospholipase A<sub>2</sub> (IPOB) were performed using Auto Dock 4.2 to investigate the binding mode of 6-amino-5-bromouracil and Gel with cobra-venom

phospholipase A<sub>2</sub> (IPOB) and to obtain information about interaction forces between 6-amino-5-bromouracil and cobra-venom phospholipase A<sub>2</sub> (IPOB). 6-Amino-5-bromouracil, gel and cobra-venom phospholipase A<sub>2</sub> (IPOB) was kept as flexible molecules and were docked into seven forms of rigid phospholipase A<sub>2</sub> to obtain the preferential binding site to 6-amino-5-bromouracil and gel on phospholipase A<sub>2</sub>. The molecular docking results are shown in **Table 1**. The modeling studies showed that there is *van der Waals*, hydrogen bonding and electrostatic interactions between 6-amino-5-bromouracil and gel with phospholipase A<sub>2</sub>. The contribution of *van der Waals* and hydrogen bonding interaction is much greater than that of the electrostatic interaction because the sum of *van der Waals* energy, hydrogen bonding energy and desolvation free energy is larger than the electrostatic energy, which is consistent with the literature [16,17]. The 6-amino-5-bromouracil, gel and cobra-venom phospholipase A<sub>2</sub> (IPOB) interactions are shown in **Figure 1**. 6-Amino-5-bromouracil showed a good binding energy (-5.52 kcal/mol) when compared to standard gel (-4.26 kcal/mol) as mentioned in **Table 1**. **Figure 1** shows four hydrogen bonds between 6-amino-5-bromouracil and cobra-venom phospholipase A<sub>2</sub> while gel shows six hydrogen bonds with cobra-venom phospholipase A<sub>2</sub>. In addition, 6-amino-5-bromouracil showed good docking interaction with the cobra-venom phospholipase A<sub>2</sub> binding site (GLY31, TYR63 and ASP48) (**Figure 1**) and similarly Gel showed good docking interaction with the cobra-venom phospholipase A<sub>2</sub> binding site (ARG30, GLY29 and ASP48). The interaction of both ligands (6-amino-5-bromouracil and Gel) with the cobra-venom phospholipase A<sub>2</sub> binding site of the enzyme is essential for effective inhibition as previously reported for gel [18,19]. Therefore, 6-amino-5-bromouracil and gel may be considered as the effective phospholipase A<sub>2</sub> inhibitor.



**Figure 1.** Shows the interaction model between 6-amino-5-bromouracil and gel with cobra-venom phospholipase A<sub>2</sub> (IPOB) active site. 6-Amino-5-bromouracil molecule was shown in green color while the gel molecule in yellow color. The hydrogen bonds are represented using green broken line.

**Table 1.** Various energies in the binding process of 6-amino-5-bromouracil and gel and cobra-venom phospholipase A<sub>2</sub> (1POB) obtained from molecular docking. The unit of all energies ( $\Delta G$ ) is kcal/mol.

| Compounds                                                                                         | Hydrogen bond formation between Cobra-venom phospholipase A <sub>2</sub> (1POB) with 6A5Bu and gel                                                                                                                                                         | Hydrogen bond distance Å                                       | Donor atom                            | Acceptor atom                        | Binding energy ( $\Delta G$ ) kcal/mol |
|---------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|---------------------------------------|--------------------------------------|----------------------------------------|
| 6-amino-5-bromopyrimidine-2,4(1H,3H)-dione or 6-amino-5-bromouracil (6A5BU)                       | GLY31:HN of <b>1pob</b> and O10 of 6A5BU<br>H2 of 6A5BU and OH of <b>1pob</b> TYR63<br>H5 of 6A5BU and OH of <b>1pob</b> ASP48<br>H3 of 6A5BU and OH of <b>1pob</b> ASP48                                                                                  | 1.75938<br>1.76047<br>1.64556<br>2.29695                       | HN<br>H2<br>H5<br>H3                  | O10<br>OH<br>OH1<br>OH1              | -5.52                                  |
| [(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl]oxy-heptylphosphinic acid (Gel) | ARG30:HN of <b>1pob</b> and O15 of gel<br>ARG30:HE of <b>1pob</b> and O15 of gel<br>ARG30:HH of <b>1pob</b> and O14 of gel<br>ARG30:HH21 of <b>1pob</b> and O15 of gel<br>H32 of gel and O of <b>1pob</b> GLY29<br>H33 of gel and OH1 of <b>1pob</b> ASP48 | 2.03948<br>2.25903<br>2.39906<br>2.49538<br>2.25109<br>2.11707 | HN<br>H<br>HH21<br>HH21<br>H32<br>H33 | O15<br>O15<br>O14<br>O15<br>O<br>OH1 | -4.26                                  |

### Fluorescence spectra and 6-amino-5-bromouracil


Fluorescence spectroscopy has proved to be helpful in studies on ligand binding. Steady-state fluorescence quenching and fluorescence polarization are the primary techniques for studying structure and function of proteins [20]. The fluorescence spectrum shows a decrease of fluorescence intensity (**Figure 2**) of the snake venom due to addition of 105  $\mu$ M of 6-amino-5-bromouracil which could be related to various processes. It is well known that a decrease in fluorescence intensity can be caused by a range of molecular interactions such as molecular rearrangements,

excited-state reactions, ground state complex formation, collisional quenching or energy transfer. The decrease in fluorescence emission intensity as shown in **Figure 2** was not accompanied any shift which may indicate that Trp residues buried in a hydrophobic environment have moved into a relatively polar environment consistent with earlier reports [21]. The decrease in fluorescence emission intensity (**Figure 2**) was accompanied was not accompanied by any shift and this may indicate that binding of 6-amino-5-bromouracil may have accomplished a conformational change that moves tryptophan into a relatively more

hydrophobic region. This explanation is consistent with Gorbenko et al. [22] who found tryptophan fluorescence is quenched by interactions with polar ligands. Binding of proteins to lipid membranes decreases ease of access to these polar ligands and consequently decreases the obtained quenching effects.

The obtained fluorescence quenching with 6-amino-5-bromouracil refers to the process that decreases the fluorescence intensity of the snake venom. Snake venom show fluorescence and the intrinsic protein fluorescence is due to aromatic amino acids, mainly tryptophan, considering that phenylalanine has a very low quantum yield and emission by tyrosine in native proteins is often quenched. The fluorescence of the snake venom is mainly due to tryptophan of phospholipase, which can be selectively measured by exciting at 295 nm, because there is no

absorption by tyrosine at this wavelength. Tryptophan fluorescence is extremely responsive to the environment polarity and shifts in its emission spectrum toward slower wavelengths (blue shift) can be observed as the increased hydrophobicity [23,24]. Changes in emission spectra from tryptophan can be seen in response to snake venom phospholipase conformational transitions, subunit association, 6-amino-5-bromouracil binding or denaturation, which affect the environment surrounding the indole ring of tryptophane. In addition, the quenching reaction obtained can be used not only to probe topological features of the phospholipase structures, but also to follow protein conformation changes that affect accessibility to tryptophan. It is reported that any treatment of the native protein that involves a change in the tryptophan environment can be followed by fluorescence quenching (Figure 2) [25,26].



**Figure 2.** (A) Plot of fluorescence emission of snake venom (*Cerastes cerastes*) (24.6 µg/ml) vs. wavelength from 288-540 nm using excitation of  $\lambda_{280}$  nm in 0.01 M Tris, 0.1 M NaCl at pH 7.4. (B) Fluorescence perturbation of snake venom by addition of 105 µM 6-amino-5-bromouracil. Spectra were corrected for small background fluorescence contributions from the buffer solution and were scaled to visualize the shift.

#### Calculation LD99 of *Cerastes cerastes* venom

Lethality data of *Cerastes cerastes* venom was calculated. The LD99 of *Cerastes cerastes* venom from this study was 5 µg/kg as reported previously [14].

#### Acute toxicity of *Cerastes cerastes* venom and its neutralization by 6-amino-5-bromouracil and anti-venom

The *Cerastes cerastes* venom at the dose 5 µg/kg (LD99) produces 100% mortality in mice. The 6-amino-5-bromouracil significantly increases the mean survival time up to  $6.3 \pm 0.23$  h. The 6-amino-5-bromouracil when used at the dose of 100 µl (stock 18.5 mM) solution was found to be more effective against *Cerastes cerastes* venom (4.8 h) when

compared with 6.2 h produced by 300 µl. ASV (polyvalent anti-snake venom by Haffkine Bio-Pharmaceuticals Company (India)) was found to be more effective as compared with the aqueous 6-amino-5-bromouracil showing mean survival of two days for five mice and complete survival of one mouse and was consistent to our previously published work [14].

The pharmacological effects of *Cerastes cerastes* venoms could be classified into three main types, neurotoxic, hemotoxic [27-29] and cytotoxic. The main toxin related to these effects is PLA<sub>2</sub>s, which is responsible for many pharmacological effects happening in snakebite victims. The PLA<sub>2</sub>s is able to operate on pre- or post-synaptic junctions as antagonist of ion channels and muscarinic or nicotinic

receptors to persuade cruel neurotoxicity such as paralysis and respiratory failure [29,30]. In addition PLA<sub>2</sub>s can cause local tissue damage resulting in blistering, swelling, necrosis, and bruising. In addition it has systemic effects such as hypovolemic shock; encourage hemostatic and cardiovascular effects as coagulopathy, hemorrhage and hypotension. It is also reported that PLA<sub>2</sub>s are able of triggering severe pain [31,32].

Because phospholipase A<sub>2</sub> (PLA<sub>2</sub>) activity is a significant part of venom toxicity, it has been required candidate PLA<sub>2</sub> inhibitors by directly testing drugs. It was observed that 6-amino-5-bromouracil when given to the mice after they received snake venom of *Cerastes cerastes* venom significantly increased mean survival time and the results were found to be better when it was used at higher dose 300 µl (stock 18.5 mM) of 6-amino-5-bromouracil solution. This could be possible due to interaction of active venom components mainly PLA<sub>2</sub> with 6-amino-5-bromouracil which is consistent with the result obtained by molecular docking.

In the literature there are few small molecules can inhibit PLA<sub>2</sub> of the snake venom and delay the toxicity of the snake venom which can support the obtained results in this paper [33,34]. It has been reported that Varespladib and methyl-varespladib (it's orally bioavailable prodrug) were able to delay the effects of twenty eight medically important snake venoms from six continents but not for long time. Also, it has been reported that varespladib and methyl-varespladib were able to suppress host response safely and are more effective against snake venom PLA<sub>2</sub> (picomolar concentrations) than against mammalian sPLA<sub>2</sub> [11]. They were able to perform protection against the injurious effects of hemorrhage, hemolysis and other tissue obliteration [35].

Results obtained by using 6-amino-5-bromouracil are not very astonishing and are in agreement with some previous studies [36-38], as one pyrimidine-2,4,6-trione has been published as a promising efficient and selective inhibitor of cell matrix metalloproteases [37,38]. Other studies have also revealed the efficiency of pyrimidine-2,4,6-trione derivatives, mainly one named RO 28-2653 developed by Hoffman-La Roche research group, in anticancer therapy [39,40]. However, 6-amino-5-bromouracil has not ever been pointed as PLA<sub>2</sub> inhibitor or been used in the neutralization of snake venom enzymes.

## CONCLUSION

Rapid development and use of a broad-spectrum PLA<sub>2</sub> inhibitor alone or in combination with other small molecule inhibitors of snake toxins might fill the dangerous therapeutic gap spanning pre-referral and hospital setting. There is an urgent need for economical, stable and effective snakebite treatments that can be used in places where medical access is limited. 6-Amino-5-bromouracil has ability to delay the snakebite envenomation make it

reasonable candidates for consideration of clinical trials and warrant further examination by skilled practitioners and basic researchers in the field of snakebite. Further elaborative work is necessary for the better understanding of the mechanism of venom inhibition. We expect that the results presented herein can motivate future efforts in finding potent pyrimidine-2,4(1H,3H)-dione derivatives that can be used for snake venom phospholipases A<sub>2</sub> inhibition *in vivo*.

## ACKNOWLEDGEMENT

The authors gratefully acknowledge the technical support and valuable suggestions obtained from Ms. Amira Abdul Gbaj.

## REFERENCES

- 1) Harrison RA, Oluoch GO, Ainsworth S, Alsolaiss J, Bolton F, et al. (2017) Preclinical anti-venom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa. PLoS Negl Trop Dis 11:e0005969.
- 2) Appiah B (2012) Snake bite neglect rampant in Africa. CMAJ 184: E27-E28.
- 3) Siddiqi AR, Shafqat J, Zaidi ZH, Jornvall H (1991) Characterization of phospholipase A2 from the venom of horned viper (*Cerastes cerastes*). FEBS Lett 278: 14-16.
- 4) Hernandez R, Cabalceta C, Saravia-Otten P, Chaves A, Gutierrez JM, et al. (2011) Poor regenerative outcome after skeletal muscle necrosis induced by *Bothrops asper* venom: Alterations in microvasculature and nerves. PLoS One 6: e19834.
- 5) Herrera C, Voisin MB, Escalante T, Rucavado A, Nourshargh S, et al. (2016) Effects of PI and PIII snake venom hemorrhagic metalloproteinases on the microvasculature: A confocal microscopy study on the mouse cremaster muscle. PLoS One 11: e0168643.
- 6) Mora J, Mora R, Lomonte B, Gutierrez JM (2008) Effects of *Bothrops asper* snake venom on lymphatic vessels: Insights into a hidden aspect of envenomation. PLoS Negl Trop Dis 2: e318.
- 7) Gay C, Marunak S, Teibler P, Leiva L, Acosta O (2013) Effect of monospecific antibodies against baltergin in myotoxicity induced by *Bothrops alternatus* venom from northeast of Argentina. Role of metalloproteinases in muscle damage. Toxicon 63: 104-111.
- 8) Herrera C, Rucavado A, Warrell DA, Gutierrez JM (2013) Systemic effects induced by the venom of the snake *Bothrops caribbaeus* in a murine model. Toxicon 63: 19-31.
- 9) Lombardo D, Dennis EA (1985) Cobra venom phospholipase A2 inhibition by manoalide. A novel type

- of phospholipase inhibitor. J Biol Chem 260: 7234-7240.
- 10) Reynolds LJ, Mihelich ED, Dennis EA (1991) Inhibition of venom phospholipases A2 by manoalide and manolide. Stoichiometry of incorporation. J Biol Chem 266: 16512-16517.
  - 11) Lewin M, Samuel S, Merkel J, Bickler P (2016) Varespladib (LY315920) appears to be a potent, broad-spectrum, inhibitor of snake venom phospholipase A2 and a possible pre-referral treatment for envenomation. Toxins (Basel) 8.
  - 12) Tiwari R, Mahasenan K, Pavlovicz R, Li C, Tjarks W (2009) Carborane clusters in computational drug design: A comparative docking evaluation using AutoDock, FlexX, Glide and Surflex. J Chem Inf Model 49: 1581-1589.
  - 13) Markwell MA, Haas SM, Bieber LL, Tolbert NE (1978) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 87: 206-210.
  - 14) Sadawe EA, Hashkel AM, Gbaj HA, Mohamed A, Magel NM, et al. (2019) *Olea europaea* leaves delay the onset of toxicity of *Cerastes cerastes* venom in Albino mice. J Pharm Res 4: 1-3.
  - 15) Cherifi F, Saoud S, Laraba-Djebari F (2018) Molecular modeling, biochemical characterization and pharmacological properties of Cc3-SPase: A platelet-aggregating thrombin-like enzyme purified from *Cerastes cerastes* venom. J Biochem Mol Toxicol 2018: e22165.
  - 16) Holt PA, Chaires JB, Trent JO (2008) Molecular docking of intercalators and groove-binders to nucleic acids using Autodock and Surflex. J Chem Inf Model 48: 1602-1615.
  - 17) Gilad Y, Senderowitz H (2014) Docking studies on DNA intercalators. J Chem Inf Model 54: 96-107.
  - 18) Scott DL, White SP, Otwinowski Z, Yuan W, Gelb MH, et al. (1990) Interfacial catalysis: The mechanism of phospholipase A2. Science 250: 1541-1546.
  - 19) White SP, Scott DL, Otwinowski Z, Gelb MH, Sigler PB (1990) Crystal structure of cobra-venom phospholipase A2 in a complex with a transition-state analogue. Science 250: 1560-1563.
  - 20) Yang Y, Zhu L, Chen X, Zhang H (2010) Binding research on flavones as ligands of beta-amyloid aggregates by fluorescence and their 3D-QSAR, docking studies. J Mol Graph Model 29: 538-545.
  - 21) Kenoth R, Simanshu DK, Kamlekar RK, Pike HM, Molotkovsky JG, et al. (2010) Structural determination and tryptophan fluorescence of heterokaryon incompatibility C2 protein (HET-C2), a fungal glycolipid transfer protein (GLTP), provide novel insights into glycolipid specificity and membrane interaction by the GLTP fold. J Biol Chem 285: 13066-13078.
  - 22) Gorbenko GP, Ioffe VM, Kinnunen PK (2007) Binding of lysozyme to phospholipid bilayers: Evidence for protein aggregation upon membrane association. Biophys J 93: 140-153.
  - 23) Bag SS, Kundu R (2013) Sensing of micellar microenvironment with dual fluorescent probe, triazolylpyrene (TNDMBPy). J Fluoresc 23: 929-938.
  - 24) Wang JZ, Lin T, Teng T, Xie SS, Zhu GF, et al. (2011) Spectroscopic studies on the irreversible heat-induced structural transition of Pin1. Spectrochim Acta A Mol Biomol Spectrosc 78: 142-147.
  - 25) Jazaj D, Ghadami SA, Bemporad F, Chiti F (2019) Probing conformational changes of monomeric transthyretin with second derivative fluorescence. Sci Rep 9: 10988.
  - 26) Chen Y, Wang M, Fu H, Qu X, Zhang Z, et al. (2019) Spectroscopic and molecular modeling investigation on inhibition effect of nitroaromatic compounds on acetylcholinesterase activity. Chemosphere 236: 124365.
  - 27) Valenta J, Stach Z, Porizka M, Michalek P (2019) Analysis of hemocoagulation tests for prediction of venom-induced consumption coagulopathy development after Viperidae bite. Bratisl Lek Listy 120: 566-568.
  - 28) Crofts SB, Lai Y, Hu Y, Anderson PSL (2019) How do morphological sharpness measures relate to puncture performance in viperid snake fangs? Biol Lett 15: 20180905.
  - 29) Esiene A, Etoundi PO, Tochie JN, Metogo AJM, Minkande JZ (2019) Severe Viperidae envenomation complicated by a state of shock, acute kidney injury and gangrene presenting late at the emergency department: A case report. BMC Emerg Med 19: 26.
  - 30) Abdel-Aty AM, Salama WH, Ali AA, Mohamed SA (2019) A hemorrhagic metalloprotease of Egyptian *Cerastes vipera* venom: Biochemical and immunological properties. Int J Biol Macromol 130: 695-704.
  - 31) Bittencourt GB, Hauzman E, Bonci DMO, Ventura DF (2019) Photoreceptors morphology and genetics of the visual pigments of *Bothrops jararaca* and *Crotalus durissus terrificus* (Serpentes, Viperidae). Vision Res 158: 72-77.

- 32) Ozverel CS, Damm M, Hempel BF, Gocmen B, Sroka R, et al. (2019) Investigating the cytotoxic effects of the venom proteome of two species of the Viperidae family (*Cerastes cerastes* and *Cryptelytrops purpureomaculatus*) from various habitats. *Comp Biochem Physiol C Toxicol Pharmacol* 220: 20-30.
- 33) Bittenbinder MA, Zdenek CN, Op dB, Youngman NJ, Dobson JS, et al. (2018) Coagulotoxic cobras: Clinical implications of strong anticoagulant actions of African spitting *Naja* venoms that are not neutralised by anti-venom but are by LY315920 (Varespladib). *Toxins (Basel)* 10.
- 34) Knudsen C, Laustsen AH (2018) Recent advances in next generation snakebite anti-venoms. *Trop Med Infect Dis* 3.
- 35) Wang Y, Zhang J, Zhang D, Xiao H, Xiong S, et al. (2018) Exploration of the inhibitory potential of varespladib for snakebite envenomation. *Molecules* 23.
- 36) Wallnoefer HG, Lingott T, Guti  rrez JM, Merfort I, Liedl KR (2011) Backbone flexibility controls the activity and specificity of a protein-protein interface "specificity in snake venom metalloproteases" (SVMs). *J Cheminform* 3: 22.
- 37) MacColl E, Khalil RA (2015) Matrix metalloproteinases as regulators of vein structure and function: Implications in chronic venous disease. *J Pharmacol Exp Ther* 355: 410-428.
- 38) Raffetto JD, Khalil RA (2008) Matrix Metalloproteinases and their inhibitors in vascular remodeling and vascular disease. *Biochem Pharmacol* 75: 346-359.
- 39) St  cker W, Grams F, Baumann U, Reinemer P, Gomis-R  th FX, et al. (1995) The metzincins - Topological and sequential relations between the astacins, adamalysins, serralyins and matrixins (collagenases) define a superfamily of zinc-peptidases. *Protein Sci* 4: 823-840.
- 40) Brandstetter H, Engh RA, Von Roedern EG, Moroder L, Huber R, et al. (1998) Structure of malonic acid-based inhibitors bound to human neutrophil collagenase. A new binding mode explains apparently anomalous data. *Protein Sci* 7: 1303-1309.